← All trials
NCT04849715
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2022
- Primary completion
- Aug 15, 2030
- Completion date
- May 13, 2034
- First posted
- Apr 19, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 516
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- IncyteLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.